Viridian Therapeutics (NASDAQ:VRDN) Earns Outperform Rating from Oppenheimer

Oppenheimer reaffirmed their outperform rating on shares of Viridian Therapeutics (NASDAQ:VRDN) in a research report report published on Monday, Benzinga reports. They currently have a $28.00 price target on the stock, down from their prior price target of $31.00.

Other research analysts have also recently issued reports about the stock. Wedbush restated an outperform rating and set a $42.00 price target on shares of Viridian Therapeutics in a report on Monday, July 29th. LADENBURG THALM/SH SH cut shares of Viridian Therapeutics from a buy rating to a neutral rating in a report on Thursday, May 9th. Wolfe Research began coverage on shares of Viridian Therapeutics in a report on Tuesday, June 11th. They set an outperform rating and a $29.00 price target on the stock. HC Wainwright restated a buy rating and set a $27.00 price target on shares of Viridian Therapeutics in a report on Tuesday, July 16th. Finally, The Goldman Sachs Group started coverage on shares of Viridian Therapeutics in a research note on Thursday, June 6th. They issued a buy rating and a $23.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Viridian Therapeutics has a consensus rating of Moderate Buy and an average target price of $31.20.

Viridian Therapeutics Trading Down 3.5 %

NASDAQ:VRDN opened at $14.18 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 23.99 and a quick ratio of 23.99. The firm has a 50-day moving average of $13.92 and a 200-day moving average of $15.47. The company has a market cap of $905.00 million, a PE ratio of -3.15 and a beta of 1.13. Viridian Therapeutics has a one year low of $10.93 and a one year high of $24.18.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Thursday, August 8th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.15). Viridian Therapeutics had a negative return on equity of 89.20% and a negative net margin of 79,185.77%. The firm had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.09 million. As a group, equities research analysts expect that Viridian Therapeutics will post -3.7 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in shares of Viridian Therapeutics by 7.8% during the 1st quarter. Vanguard Group Inc. now owns 3,234,279 shares of the company’s stock valued at $56,632,000 after buying an additional 233,331 shares in the last quarter. Perceptive Advisors LLC lifted its stake in shares of Viridian Therapeutics by 71.1% during the 4th quarter. Perceptive Advisors LLC now owns 1,730,212 shares of the company’s stock valued at $37,684,000 after buying an additional 719,007 shares in the last quarter. Vestal Point Capital LP purchased a new stake in shares of Viridian Therapeutics during the 4th quarter valued at approximately $21,780,000. Candriam S.C.A. lifted its stake in shares of Viridian Therapeutics by 167.8% during the 2nd quarter. Candriam S.C.A. now owns 749,804 shares of the company’s stock valued at $9,754,000 after buying an additional 469,804 shares in the last quarter. Finally, RTW Investments LP purchased a new stake in shares of Viridian Therapeutics during the 4th quarter valued at approximately $13,195,000.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.